* Ono Pharma soars to highest since Aug. 2016
* Shimamura tumbles after cutting profit forecast
By Ayai Tomisawa
TOKYO, Oct 2 (Reuters) - Japan's Nikkei edged up to a fresh 27-year high on Tuesday, building on recent strength thanks to upbeat earnings hopes, while Ono Pharmaceutical surged on news that a Nobel Prize was awarded to researchers for a cancer-fighting method used in its drug Opdivo.
The Nikkei share average .N225 ended 0.1 percent higher at 24,270.62, hovering at levels not seen since November 1991.
The gains in the benchmark have been underpinned by the prospect of stronger corporate earnings on the back of a weaker yen. The benchmark index has comfortably stayed above the 24,000-line since last Friday.
The Nikkei rallied 5.5 percent in September, and its sharp gains in the short-period of time make the market prone to profit-taking, but the underlining mood remains positive, traders said.
"Investors take heart from the global economy's strength and prospects for brighter earnings forecasts as they start reporting earnings later this month," said Takuya Takahashi, a strategist at Daiwa Securities.
While many companies based their dollar-yen assumptions at around 105-107 this fiscal year, the current levels are boosting hopes that manufacturers, which export their goods overseas, will raise their annual earnings forecasts, he said.
The dollar surged to as high as 114.06 yen in the previous session, its strongest since November last year, before trading flat at 113.77 yen on Tuesday.
Exporters got a boost, with Toyota Motor Corp 7203.T rising 1.6 percent, Honda Motor Co
Shares of Ono Pharmaceutical Co 4528.T jumped as much as 6.9 percent to hit 3,430 yen, the highest level since August 2016, before ending up 3.1 percent on news that a Nobel Prize was awarded to researchers for a cancer-fighting method used in Opdivo, a drug it co-developed with Bristol-Myers Squibb Co BMY.N . the weak side, discount clothing chain Shimamura Co 8227.T tumbled 8.2 percent after the company revised lower its earnings forecast for the year ending February 2019. It now expects a net profit of 27.3 billion yen, down from previously forecast 35 billion yen.
The broader Topix .TOPX was up 0.3 percent at 1,824.03.
(Editing by Kim Coghill & Shri Navaratnam)
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.